{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T15:14:28Z","timestamp":1700406868902},"reference-count":34,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T00:00:00Z","timestamp":1442534400000},"content-version":"unspecified","delay-in-days":5404,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Therapy-resistance for positive symptoms is one of the most important problems that occurs with the medical treatment of schizophrenia. In the past years, clozapine has proven its effectiveness in this area and has been included in the treatment protocols and guidelines. Because of the risk of agranulocytosis with this compound and the intensive laboratory controls to be done, several studies have been performed with the new antipsychotics risperidone and olanzapine as alternative treatments. A review of the literature suggests that both drugs are as effective as the classic antipsychotics for therapy-resistant patients. A switch to risperidone or olanzapine possibly would be a alternative for those patients who have favourable effects on a low dose of clozapine. Furthermore the new antipsychotics have less side effects and ameliorating effects on negative and cognitive symptoms, so contributing to overall improvement in chronic schizophrenic disorders. However, in case of persistent positive symptopathology, clozapine remains the golden standard. The new antipsychotics should be included in treatment protocols before clozapine.<\/jats:p>","DOI":"10.1017\/s0924270800035365","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T05:24:29Z","timestamp":1469510669000},"page":"183-192","update-policy":"http:\/\/dx.doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of risperidone, olanzapine and clozapine in the treatment of therapy resistant schizophrenia"],"prefix":"10.1017","volume":"12","author":[{"given":"M.","family":"Wardenier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.","family":"Slooff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Arends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2015,9,18]]},"reference":[{"key":"S0924270800035365_ref012","doi-asserted-by":"publisher","DOI":"10.3109\/15622970009150570"},{"key":"S0924270800035365_ref031","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442565"},{"key":"S0924270800035365_ref003","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000059"},{"key":"S0924270800035365_ref027","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.4.499"},{"key":"S0924270800035365_ref002","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"S0924270800035365_ref005","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199804001-00003"},{"key":"S0924270800035365_ref007","volume-title":"Behandelingsstrategie\u00ebn bij Schizofrenie","author":"Slooff","year":"1999"},{"key":"S0924270800035365_ref019","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.7.914"},{"key":"S0924270800035365_ref022","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1992.tb01473.x"},{"key":"S0924270800035365_ref025","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199502001-00008"},{"key":"S0924270800035365_ref008","first-page":"18","article-title":"Some adverse effects of antipsychotics: prevention and treatment","author":"Lader","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"S0924270800035365_ref006","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/S000712500029692X","article-title":"Dimensions of outcome with clozapine","volume":"160","author":"Meitzer","year":"1992","journal-title":"Br J Psychiatry"},{"key":"S0924270800035365_ref004","volume-title":"The Bethlem and Maudslcy NHS Trust Prescribing Guidelines","author":"Taylor","year":"1999"},{"key":"S0924270800035365_ref009","article-title":"Treatment of the refractory schizophrenic patient","volume":"59","author":"Daniel","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"S0924270800035365_ref010","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00849.x"},{"key":"S0924270800035365_ref011","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry"},{"key":"S0924270800035365_ref014","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199710000-00010"},{"key":"S0924270800035365_ref016","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n1003"},{"key":"S0924270800035365_ref028","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n1105"},{"key":"S0924270800035365_ref029","first-page":"187","volume-title":"The effects on psychomotor performance: Proceedings of the 10th Biennial Winterworkshop on schizophrenia: 2000","volume":"41","author":"Oliemeulen","year":"2000"},{"key":"S0924270800035365_ref017","first-page":"31","article-title":"Selecting an atypical antipsychotic by combining clinical experiences with guidelines from clinical trials","volume":"60","author":"Stahl","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"S0924270800035365_ref018","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.156.9.1374","article-title":"Risperidone in treatment-refractory schizophrenia","volume":"156","author":"Wirshing","year":"1999","journal-title":"Am J Psychiatry"},{"key":"S0924270800035365_ref020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0924-977X(98)80379-9","article-title":"An investigation of subgroup effects in a study of olanzapine versus clozapine in the treatment of resistant schizophrenic patients","volume":"8","author":"Bcuzcn","year":"1998","journal-title":"Eur Neuropsvchopharmacol"},{"key":"S0924270800035365_ref013","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schziofre-niform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"S0924270800035365_ref021","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v57n1004"},{"key":"S0924270800035365_ref024","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00291-1"},{"key":"S0924270800035365_ref026","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"Am J Psychiatry"},{"key":"S0924270800035365_ref032","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1999.tb07230.x"},{"key":"S0924270800035365_ref030","volume-title":"Newer Antipsychotic Medication Versus Clozapine For Schizophrenia","author":"Tuunaincn","year":"1999"},{"key":"S0924270800035365_ref034","volume-title":"Cogntive behavior therapy for schizophrenia","volume":"1998","author":"Jones"},{"key":"S0924270800035365_ref015","volume-title":"Risperidone versus olanzapine in patients with schizophrenia and schizoaffective distorder","author":"Conley","year":"1999"},{"key":"S0924270800035365_ref033","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979590"},{"key":"S0924270800035365_ref023","first-page":"18","article-title":"Efficacy of risperidone on positive features of schizophrenia","volume":"55","author":"McEvoy","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"S0924270800035365_ref001","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033315"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270800035365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T09:53:49Z","timestamp":1692438829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270800035365\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["S0924270800035365"],"URL":"https:\/\/doi.org\/10.1017\/s0924270800035365","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]},"assertion":[{"value":"Copyright \u00a9 Scandinavian College of Neuropsychopharmacology 2000","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}